Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$1.48	$1.48	$0.63 ▼ $1.51	$60.83M	1.25	674,735 shs	N/A
IKT Inhibikase Therapeutics	$1.64 -0.5%	$1.96	$1.12 ▼ $4.20	$123.04M	0.94	244,343 shs	81,430 shs
PLX Protalix BioTherapeutics	$1.50 +3.1%	$1.94	$0.82 ▼ $3.10	$119.01M	-0.2	561,394 shs	234,830 shs
TCRR TCR2 Therapeutics	$1.48	$1.65	$0.82 ▼ $3.88	$58.11M	1.95	494,777 shs	N/A

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	0.00%	+75.56%
IKT Inhibikase Therapeutics	-1.20%	-2.94%	-6.78%	-27.95%	+17.02%
PLX Protalix BioTherapeutics	+2.84%	+3.57%	-7.05%	-43.80%	+17.89%
TCRR TCR2 Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	1.4989 of 5 stars	3.3	1.0	0.0	0.0	0.0	0.0	1.3
PLX Protalix BioTherapeutics	2.6855 of 5 stars	3.5	4.0	0.0	0.0	0.6	0.0	1.9
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	296.10% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	903.34% Upside
TCRR TCR2 Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TCRR, IKT, PLX, and ACHL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
IKT Inhibikase Therapeutics	$260K	469.21	N/A	N/A	$1.78 per share	0.92
PLX Protalix BioTherapeutics	$59.76M	1.99	$0.08 per share	17.80	$0.47 per share	3.18
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	$2.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	8/12/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.82	N/A	-21.03%	-30.89%	-11.74%	N/A
TCRR TCR2 Therapeutics	-$151.82M	-$4.20	N/A	N/A	N/A	N/A	-97.81%	-69.35%	N/A

Latest TCRR, IKT, PLX, and ACHL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	6.04	6.04
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PLX Protalix BioTherapeutics	N/A	1.98	1.27
TCRR TCR2 Therapeutics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
IKT Inhibikase Therapeutics	3.81%
PLX Protalix BioTherapeutics	16.53%
TCRR TCR2 Therapeutics	64.76%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
IKT Inhibikase Therapeutics	7.30%
PLX Protalix BioTherapeutics	6.50%
TCRR TCR2 Therapeutics	25.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
TCRR TCR2 Therapeutics	137	39.26 million	29.44 million	Not Optionable

TCRR, IKT, PLX, and ACHL Headlines

Recent News About These Companies

TCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatment

April 17, 2024 | pharmaceutical-technology.comP

Poseida Therapeutics Inc Ordinary Shares PSTX

February 25, 2024 | morningstar.comM

DICE Therapeutics Inc.

June 20, 2023 | wsj.com

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

June 1, 2023 | finance.yahoo.com

TCR2 Therapeutics Insider Trades Send a Signal

May 16, 2023 | benzinga.com

Recap: TCR2 Therapeutics Q1 Earnings

May 12, 2023 | msn.com

10-Q: TCR2 THERAPEUTICS INC.

May 11, 2023 | marketwatch.com

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023 | finance.yahoo.com

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky

April 15, 2023 | finance.yahoo.com

Mizuho Downgrades Tcr2 Therapeutics (TCRR)

March 25, 2023 | msn.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securities

March 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)

March 23, 2023 | markets.businessinsider.com

TCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finanznachrichten.de

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finance.yahoo.com

What To Know About Jefferies's Downgrade of TCR2 Therapeutics

March 9, 2023 | msn.com

4 Analysts Have This to Say About TCR2 Therapeutics

March 9, 2023 | markets.businessinsider.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwright

March 8, 2023 | markets.businessinsider.com

Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune

March 6, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyout

March 6, 2023 | benzinga.com

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

March 6, 2023 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRR, IKT, PLX, and ACHL Company Descriptions

Achilles Therapeutics NASDAQ:ACHL

$1.48 0.00 (0.00%)

As of 03/26/2025

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Inhibikase Therapeutics NYSE:IKT

$1.64 -0.01 (-0.55%)

As of 11:58 AM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Protalix BioTherapeutics NYSE:PLX

$1.50 +0.05 (+3.10%)

As of 11:59 AM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time